Note: Descriptions are shown in the official language in which they were submitted.
Le A 31 477- Foreign countries / Sto/mlS-P 2 1 ~ 4 9 4 ~
I
2-Oxo- and 2-thio-1.2-dihyd~quinolinyl-oxazolidinones
The present invention relates to 2-oxo- and 2-thio- 1,2-dihydroquinolinyl-oxazolidinones,
processes for their l)repa~lion and their use as medicaments, in particular as
antibacterial medicaments.
5 N-Aryloxazolidinones having antibacterial action are disclosed, for example, in the
publication EP 311 090. 3-(Nitrogen-substituted)phenyl-S-beta-amidomethyloxazolidin-
2-ones are additionally disclosed in EP 609 905 A1.
Furthermore, oxazolidinone derivatives having a mono~rnine oxidase-inhibitory action
are published in WO 93 08 179 A and oxazolidinone derivatives having action as
adhesion receptor antagonists are published in EP 645 376.
The present invention relates to 2-oxo- and 2-thio- 1,2-dihydroquinolinyl-oxazolidinones
of the general formula (I)
A:~L Ij,
in which
I S A represents an oxygen or a sulphur atom,
D represents hydrogen or cycloalkyl having 3 to 6 carbon atoms, or
represents straight-chain or branched alkoxycarbonyl having up to 4 carbon
atoms, or
represents straight-chain or branched alkyl or alkenyl each having up to 9
carbon atoms, which is optionally substituted by cyano, trifluoromethyl,
Le A 31 477- Forei~n countries 2 1 q 4 9 4 5
- 2 -
halogen, hydroxyl, pyridyl, phenyl, carboxyl, carboxamido, straight-chain or
branched alkoxycarbonyl having up to 5 carbon atoms, naphthyl, cycloalkyl
having 3 to 6 carbon atoms, and/or by a group of the formula -(Co)~-NR~R3,
R--I SO2 R ~
R6R7-N-So2- or Rs-S(O)b,
in which
a denotes a number 0 or 1,
R~, R3, R4, R6 and R7 are identical or dirr~lenl and
denote hydrogen, straight-chain or branched alkyl having up to 5 carbon
atoms or phenyl,
or
R~ and R3, together with the nitrogen atom, form a morpholinyl,
thiomorpholinyl, pyrrolidinyl, piperazinyl or piperidyl ring, each of
which is optionally substituted, also via the free N function, by straight-
chain or branched alkyl or acyl each having up to 4 carbon atoms,
b denotes a number 0, 1 or 2,
Rs and R3 are identical or different and
denote straight-chain or branched alkyl having up to 6 carbon atoms,
benzyl, phenyl or tolyl,
or
D represents straight-chain or branched acyl having up to 5 carbon atoms, which
21 94945
Le A 31 477- Foreign countries
- 3 -
is optionally substituted by trifluoromethyl, trichloromethyl or a group of the
formula -oR9,
in which
R9 denotes hydrogen or straight-chain or branched alkyl having up to 5
carbon atoms, which is optionally substituted by phenyl or naphthyl,
or
D l~,plesen~s a group of the formula -(CT)d-NR'R", -(Co)e-NR'2-Co-NR'3R'4, -
NR~5-So2R~6, R~7RI8-N-So2-, R~9-S(o)~ or -CO-R20,
in which
T denotes an oxygen or sulphur atom,
d and e are identical or different and have the meaning of a
indicated above and are identical to or different from this,
R~, R~, R~, R~3, R~4, R~5, R~7 and Rl3 have the meaning of R', R3 and R4 in
each case indicated above and are identical to or different from this,
f has the meaning of b indicated above and is identical to or different
from this,
Rl6 and R'9 are identical or different and have the meaning of R5 and R8
indicated above,
R20 denotes aryl having 6 to 10 carbon atoms, which is optionally
substituted by halogen,
2 1 94~5
Le A 31 477- Forei~n countries
- 4 -
E and L are identical or different and
represent hydrogen, carboxyl, halogen, cyano, formyl, trifluoromethyl, nitro,
or represents straight-chain or branched alkyl having up to 4 carbon atoms,
R~ l~;pleselll~ azido, hydroxyl or a group of the formula -oR2', O-SO,R" or
S NR23R24
in which
R2' denotes straight-chain or branched acyl having up to 6 carbon atoms or
a hydroxyl protective group,
R2~ denotes straight-chain or branched alkyl having up to 5 carbon atoms,
phenyl or tolyl,
R23 and R'4 are identical or different and
denote cycloalkyl having 3 to 6 carbon atoms, hydrogen, phenyl or
straight-chain or branched alkoxy having up to 6 carbon atoms, tert-
butoxycarbonyl, fluorenyloxycarbonyl or benzyloxycarbonyl, or
denote straight-chain or branched alkyl having up to 6 carbon atoms,
which is optionally substituted by cyano or alkoxycarbonyl having up to
4 carbon atoms,
or
R23 and/or R24 denotes a group of the formula -CT'-R25, P(o)(oR26)(oR27) or
-SO2-R~8,
in which
T' has the meaning of T indicated above and is identical to or
different from this,
~_~ 2 I q 4 9 4 5
Le A 31 477- Foreign countries
R25 denotes cycloalkyl having 3 to 6 carbon atoms, trifluoromethyl
or straight-chain or branched alkoxy having up to 6 carbon
atoms, phenyl, benzyloxy or hydrogen, or
denotes straight-chain or branched alkyl having up to 6 carbon
atoms, which is optionally substituted by straight-chain or
branched alkoxycarbonyl having up to S carbon atoms, cyano,
fluorine, chlorine, bromine or trifluoromethyl, or
denotes straight-chain or branched thioalkyl or acyl each having
up to 5 carbon atoms, or
denotes a group of the formula -NR29R30,
in which
R29 and R30 are identical or dirre~ and denote hydrogen,
phenyl or straight-chain or branched alkyl having
up to 4 carbon atoms, or
R26 and R27 are identical or dirreiel-t and denote hydrogen or straight-chain
or branched alkyl having up to 4 carbon atoms,
R28 denotes straight-chain or branched alkyl having up to 4 carbon
atoms or phenyl,
and their salts and isomers.
Physiologically acceptable salts of the oxazolidinones according to the invention can be
salts with mineral acids, carboxylic acids or sulphonic acids. Particularly preferred salts
are, for example, those with hydrochloric acid, hydrobromic acid, sulphuric acid,
- phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid,
benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic
acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
21 94945
Le A 31 477- Forei~n countries
-- 6 --
Salts which may be mentioned are furthermore salts with customary bases, such as, for
example, alkali metal salts (e.g. sodium or potassium salts), alkaline earth metal salts
(e.g. calcium or magnesium salts) or ammonium salts derived from ammonia or organic
arnines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine,
procaine, dibenzylamine, N-methylmorpholine, dihydroabietylamine, 1-ephenamine or
methyl-piperidine .
Reaction products with C,-C4-alkyl halides, in particular C,-C4-alkyl iodides, can
additionally function as salts.
The compounds according to the invention can exist in stereoisomeric forms whichbehave either as image and mirror image (enantiomers), or which do not behave asimage and mirror image (diastereomers). The invention relates both to the enantiomers
or diastereomers or to their respective mixtures. Like the diastereomers, the racemic
forms can be separated into the stereoisomerically uniform constituents in a known
manner.
Preferred compounds of the general formula (I) are those
in which
A represents an oxygen or a sulphur atom,
D represents hydrogen, cyclopropyl, cyclopentyl or cyclohexyl, or
represents straight-chain or branched alkoxycarbonyl having up to 3 carbon
atoms, or
represents straight-chain or branched alkyl or alkenyl each having up to 6
carbon atoms, which is optionally substituted by cyano, trifluoromethyl,
fluorine, chlorine, bromine, hydroxyl, pyridyl, phenyl, carboxyl, carboxamido,
straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,
naphthyl, cyclopropyl, cyclopentyl or cyclohexyl and/or by a group of the
formula -(Co)-NR~R3, R4-N-So,-Rs, R6R7-N-So~- or R8-S(O)b,
~~ Le A 31 477- Foreign countries 2 1 9 4 ~ 4 5
-- 7 --
in which
a denotes a number 0 or 1,
R', R3, R~, R6 and R7 are identical or different and
denote hydrogen, straight-chain or branched alkyl having up to 3 carbon
S atoms or phenyl,
or
R' and R3, together with the nitrogen atom, form a morpholinyl,
thiomorpholinyl, pyrrolidinyl, pipe~ y~ or piperidyl ring, each of
which is optionally ~ub~ ed also via the free N function, by straight-
chain or branched alkyl or acyl each having up to 3 carbon atoms,
b denotes a number 0, 1 or 2,
R5 and R8 are identical or different and
denote straight-chain or branched alkyl having up to 4 carbon atoms,
benzyl, phenyl or tolyl,
or
D represents straight-chain or branched acyl having up to 4 carbon atoms, which
is optionally substituted by trifluoromethyl, trichloromethyl or a group of the
formula -oR9,
in which
R9 denotes hydrogen or straight-chain or branched alkyl having up to 4
carbon atoms, which is optionally substituted by phenyl or naphthyl,
21 94945
`~ Le A 31 477- Forei~n countries
-- 8 --
or
D represents a group of the formula -(CT)d-NRIR", -(CO)e-NR'--CO-NR'-'R'4, -
NR -SO2R , R R -N-SO~-, R -S(O)f or -CO-R-,
in which
S T denotes an oxygen or sulphur atom,
d and e are identical or different and
have the m~nin~ of a indicated above and are identical to or different
from this,
R~, R~, R~2, R~3, R~4, Rl5, R'7 and Rl8 have the me~ning of R2, R3 and R4
in each case indicated above and are identical to or dirrelent from this,
f has the meaning of b indicated above and is identical to or different
from this,
Rl6 and R'9 are identical or different and have the meaning of R5 and Rg
indicated above,
R20 denotes phenyl or naphthyl, which is optionally substituted by fluorine,
chlorine or bromine,
E and L are identical or different and
represent hydrogen, fluorine, chlorine, bromine, cyano, methyl or
trifluoromethyl,
R' represents azido, hydroxyl or a group of the formula -oR2', O-SO2R22 or
NR23R24
; 21 94945
~ Le A 31 477- Foreign countries
g
in which
R2' denotes straight-chain or branched acyl having up to 5 carbon atoms or
benzyl,
R22 denotes straight-chain or branched alkyl having up to 4 carbon atoms,
S phenyl or tolyl,
R23 and R24 are identical or different and
denote cyclopropyl, cyclopentyl, cyclohexyl, hydrogen, phenyl or
straight-chain or branched alkoxy having up to 5 carbon atoms, tert-
butoxycarbonyl or benzyloxycarbonyl, or
denote straight-chain or branched alkyl having up to 4 carbon atoms,
which is optionally substituted by cyano or by straight-chain or branched
alkoxycarbonyl having up to 3 carbon atoms,
or
R23 and/or R~4 denotes a group of the formula -CT'-R25, P(o)(oR26)(oR27) or
15 -S2 R28,
in which
T' has the meaning of T indicated above and is identical to or
different from this,
R25 denotes cyclopropyl, cyclopentyl, cyclohexyl, trifluoromethyl or
straight-chain or branched alkoxy having up to 5 carbon atoms,
phenyl, benzyloxy or hydrogen, or
- denotes straight-chain or branched alkyl having up to 5 carbon
atoms, which is optionally substituted by straight-chain or
branched alkoxycarbonyl having up to 4 carbon atoms, cyano,
2 1 94945
~ Le A 31 477- Foreign countries
- 10 -
fluorine, chlorine, bromine or trifluoromethyl, or
denotes straight-chain or branched thioalkyl or acyl each having
up to 4 carbon atoms, or
denotes a group of the formula -NR~9R30,
in which
R'9 and R30 are identical or different and denote hydrogen,
phenyl or straight-chain or branched alkyl having up to
3 carbon atoms,
R26 and R27 are identical or dirrerell~ and denote hydrogen or straight-chain
or branched alkyl having up to 3 carbon atoms,
R28 denotes straight-chain or branched alkyl having up to 3 carbon
atoms or phenyl,
and their salts and isomers.
Particularly preferred compounds of the general formula (I) are those
in which
A represents an oxygen or a sulphur atom,
D represents hydrogen, cyclopropyl, cyclopentyl, cyclohexyl, allyl or straight-chain
or branched alkyl having up to 5 carbon atoms, which is optionally substituted
by cyano, hydroxyl, trifluoromethyl, fluorine, chlorine, phenyl, carboxyl,
carboxamido, straight-chain or branched alkoxycarbonyl having up to 3 carbon
atoms, cyclopropyl, cycloper~tyl or cyclohexyl and/or by a group of the formula
(CO) NR2R3 R4-N-So2-R5, R6R7N-So2- or R-S(O)b,
21 94945
"~ Le A 31 477- Forei~n countries
I I
in which
a denotes a number 0 or 1,
R', R3, R4, R6 and R7 are identical or di~erellt and denote hydrogen or
methyl,
5 b denotes a number 0, 1 or 2,
R5 and Rg are identical or different and
denote straight-chain or branched alkyl having up to 3 carbon atoms,
benzyl, phenyl or tolyl,
or
10 D represents a group of the formula -(CT)d-NR'R", -(Co)e-NR'2-Co-NR'3R'4, -
NR~5-So,R~6, R~7R~8N-So~-, R~9-S(O)~ or -CO-R~,
in which
T denotes an oxygen or sulphur atom,
d and e are identical or different and
have the me~ning of a indicated above and are identical to or different from
this,
R', R'l, R'', Rl3, Rl4, Rl5, Rl' and Rl3 have the meaning of R2, R3 and R4
in each case indicated above and are identical to or different from this,
f has the meaning of b indicated above and is identical to or different from
this,
21 94945
Le A 31 477- Forei~n countries
- 12 -
Rl6 and R~9 are identical or different and have the meaning of R5 and R8
indicated above,
R20 denotes phenyl or naphthyl, which is optionally substituted by fluorine.
chlorine or bromine,
S E and L are identical or different and re~ selll hydrogen or fluorine,
R' represents azido, hydroxyl or a group of the forrnula -oR2', O-SO2R22 or
_NR23R24
in which
R2' denotes straight-chain or branched acyl having up to 4 carbon atoms,
.. 10 R22 denotes methyl or tolyl,
R23 and R24 are identical or different and
denote cyclopropyl, hydrogen, phenyl or straight-chain or branched
alkoxy having up to 4 carbon atoms, tert-butoxycarbonyl or
benzyloxycarbonyl, or
denote straight-chain or branched alkyl having up to 3 carbon atoms,
which is optionally substituted by cyano or methoxycarbonyl,
or
R23 and/or R24 denotes a group of the forrnula -CT'-R2s,
in which
T' has the meaning of T indicated above and is identical to or
different from this,
:, 21 949~5
'~ Le A 31 477- Foreign countries
- 13 -
R~5 denotes cyclopropyl, cyclopentyl, cyclohexyl, trifluoromethyl or
straight-chain or branched alkoxy having up to 4 carbon atoms~
phenyl, benzyloxy or hydrogen, or
denotes straight-chain or branched alkyl having up to 4 carbon
atoms, which is optionally substituted by straight-chain or
branched alkoxycarbonyl having up to 3 carbon atoms, cyano,
fluorine, chlorine, bromine or trifluoromethyl, or
denotes straight-chain or branched thioalkyl or acyl each having
up to 3 carbon atoms, or
denotes a group of the formula -NR29R30,
in which
R29 and R30 are identical or different and denote hydrogen,
phenyl, methyl or ethyl,
and their salts and isomers.
15 Very particularly preferred compounds of the general formula (I) are those
in which
E and L represent hydrogen and the oxazolidinone radical is bonded to the
1,2-dihydroquinolinyl ring in position 6 or 7.
Processes for the ~olepaldlion of the compounds of the general formula (I) according to
20 the invention have additionally been found, characterized in that
[A] N-oxides of the general formula (II)
21 94945
Le A 31 477- Forei~n countries
- 14 -
N+ E ~ (II),
~ ~R1
in which
E and L have the me~ning indicated above
and
5 R' has the meaning indicated above, but preferably lep,ese~ the radical of the formula -NH-CO-NR;I,
in which
R3' denotes straight-chain or branched alkyl having up to 4 carbon atoms,
are first converted by reaction with Ac,O or p-TsCl/K,CO3 in inert solvents into the
10 compounds of the general formula (Ia)
~ N O
in which
R', E and L have the meaning indicated above
21 94945
Le A 31 477- Foreign countries
- 15 -
and
A' represents oxygen,
or
[B] compounds of the general formula (Ib)
O I ~E J~ (Ib)
~J Ij~NH R
in which
E and L have the me~ning indicated above
and R3' represents C,-C4-acyl or alkoxycarbonyl,
are reacted with alkylating agents of the general formula (III)
D'-X (III),
in which
D' has the meaning indicated above but does not represent hydrogen
and
X represents trifluoromethanesulphonate or halogen,
21 94945
Le A 31 477- Forei~n countries
- 16 -
in inert solvents and in the presence of a base,
and, if approp~;ate, the other substituents mentioned under R~ are introduced bycustomary methods,
or
5 [C] compounds of the general formula (IV)
A' N ~l (IV)
~,~ NH-C02-CH2-C6H5
in which
A', D', E and L have the meaning indicated above,
are first converted by reaction with lithium alkyls in ethers and R-glycidyl butyrate of
10 the formula (V)
o
~ ~f (CH2)3-CH3 (V)
into the compounds of the general formula (Ic)
A'~ ~ I ~OH
Le A 31 477- Forei~n countries 2 1 9 4 ~ 4 5
-- I 7 --
in which
A', D', E and L have the me~ninE~ indicated above,
which are converted by reaction with (C,-C4)-alkyl or phenylsulphonyl chlorides in
inert solvents and in the presence of a base into the corresponding compounds of the
5 general formula (Id)
A~ I ~OSO2R22
in which
A', D', E, L and R77 have the meaning indicated above,
then, using sodium azide in inert solvents, the azides of the general formula (Ie)
A~ N O (le),
~N3
in which
A', D', E and L have the meaning indicated above,
are prepared,
Le A 31 477- Forei~n countries 2 1 9 4 9 4 5
- 18 -
which are converted in a further step by reaction with alkyl phosphites or PPh3,preferably (CH30)3P, in inert solvents and with acids into the amines of the general
formula (If)
A~ ~NH2
5 in which
A', D', E and L have the mÇ~ning indicated above,
and by reaction with acetic anhydride or other acylating agents of the general formula
(VI)
R3~~CT'~R2S (VI),
10 in which
R25 and T' have the meaning indicated
and
R32 represents halogen, preferably chlorine or the radical -oCoR25,
in inert solvents the com ~unds of the general formula (Ig)
21 94945
Le A 31 477- Foreign countries
- 19 -
E O
A~N~LN O (Ig),
~ NH-Cr-R25
in which
A', D', E, L, T' and R25 have the me~ning indicated above
are prepared,
S and if A = S, for example, compounds of the general forrnula (Ig) are subjected to a
sulphurization of the amide function using Lawesson's reagent or P2S5 in toluene or 1,2-
dimethoxyethane .
The process variants according to the invention can be illustrated by way of example
by the following reaction scheme:
21 94945
- Le A 31 477- Forei~n countries
- - 20 -
[A] O
~NJ~O H ~TsCI, K2C03,
CHC13
N~CH3
H O
N J~ o H
N ~ CH3
[B] H
~N~O H CH31, K2C03,
DMF
N~CH3
N J~ O H
L ~ I
N ~ CH3
~1 ~4945
Le A 31 477- Forei~n countries - 21 -
CH3
~N O I L~ sson'sreagen~,
~f ~ - 1,2-DME,
~N o H
\~N ~~
[C] ~ Ph
1. n-BuLi, THF
N O~Ph 2. ~o~
~Ph -78C -~ RT
~N~O Cl5O2CH3. NEb. CH2CI2
OH
~Ph
NaN3,DMF/70~C
OSO2CH3
~_ 2 i ~4945
Le A 31 477- Forei~n countries
- 22 -
Ph
~NJ~O 1. (MeObP, 1 ,2-DME, 90C
I l 2.6NHCI,90C
N3
~Ph
~NJ~O ~ , THF. NEt3. -5C
--~ NH2 x HCI
~Ph
N O H
O
Suitable solvents, depending on the individual process steps, are the customary solvents
which do not change under the reaction conditions. These preferably include alcohols
such as methanol, ethanol, propanol or isop~opallol, or ethers such as diethyl ether,
S dioxane, 1,2-dimethoxyethane, tetrahydrofuran, glycol dimethyl ether or tert-butyl
methyl ether, or ketones such as acetone or butanone, or arnides such as
dimethylformamide or hexamethylphosphoramide, or hydrocarbons such as hexane,
benzene, dichlorobenzene, xylene or toluene, or dimethyl sulphoxide, acetonitrile, ethyl
a etate, or halohydrocarbons such as methylene chloride, chloroform or carbon
10 tetrachloride, or pyridine, picoline or N-methylpiperidine. Mixtures of the solvents
mentioned can also be used.
- l_ 21 94945
Le A 31 477- Foreign countries
- 23 -
Suitable bases, depending on the individual process steps, are the customary inorganic
or organic bases. These preferably include alkali metal hydroxides such as, for
example, sodium or potassium hydroxide, or alkali metal carbonates such as sodium or
potassium carbonate, or alkali metal alkoxides such as, for example, sodium or
potassium methoxide, or sodium or potassium ethoxide, or organie amines such as
ethyldiisopropylamine, triethylamine, picoline, pyridines or N-methylpiperidine, or
arnides such as sodium amide or lithium diisopropylamide, or lithium N-
silyalkylamides, such as, for example, lithium N-(bis)triphenylsilylamide or lithium
alkyls such as n-butyllithium.
The base is employed in an amount of from 1 mol to 10 mol, preferably from 1 mol to
3 mol, based on 1 mol of the compounds of the general formulae (Ib), (II), (III) and
(IV).
All reactions are in general carried out at normal, elevated or at reduced pressure (e.g.
0.5 to 5 bar). In general, the reactions are carried out at normal pressure.
Suitable solvents for the alkylation are customary organic solvents which do not change
under the reaction conditions. These preferably include ethers such as diethyl ether,
dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons- such as benzene,
toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenohydrocarbons
such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene,trichloroethylene or chlorobenzene, or ethyl acetate, or triethylamine, pyridine, dimethyl
sulphoxide, dimethylformamide, acetonitrile, acetone or nitromethane. It is also possible
to use mixtures of the solvents mentioned. Acetonitrile, dimethyl sulphoxide anddimethylformamide are preferred.
The alkylation is carried out in the abovementioned solvents at temperatures of from
0C to +150C, preferably at room temperature to +100C, at normal pressure.
The first step of the process [B] takes place in one of the abovementioned ethers using
lithium alkyl compounds or lithium N-silylamides, such as, for example, n-butyllithium,
21 94945
Le A 31 477- Foreign countries
- 24 -
lithium diisopropylamide or lithium bistrimethylsilylamide, preferably in
tetrahydrofuran and lithium bis-trimethylsilylamide or n-butyllithium, in a temperature
range from -100C to +20C, preferably from -75C to -40C.
In addition, solvents employed for the individual steps are those mentioned above,
5 preferably methylene chloride, dimethylformamide and 1,2-dimethoxyethane
The acylation is in general carried out in one of the abovementioned ethers or
halogenohydrocarbons, preferably tetrahydrofuran or methylene chloride, in a
telllpeldlule range from -30C to 50C, preferably from -10C to room telll~el~lule.
The compounds of the general formula (II) are new and can be prepared by
10 reacting compounds of the general formula (VII)
N E o
N ~ O (VII)
L ~ R'
in which
R', E and L have the meaning indicated above,
in one of the abovementioned solvents, preferably in methylene chloride, with oxidizing
15 agents such as, for example, metachloroperbenzoic acid, hydrogen peroxide or peracetic
acid, preferably with metachloroperbenzoic acid, in a temperature range from 0C to
80C, preferably from 0C to 40C.
The compounds of the general formula (VII) can be prepared by re~cting, in analogy
to the abovementioned process [C], compounds of the general formula (VIII)
- ~1 94945
Le A 31 477- Forei~n countries
E ~ 25 -
NH-CO2-CH2~c6Hs (VIII),
L
in which
E and L have the me~ning indicated above,
with the epoxide of the formula (IV) and starting from the free hydroxyl function,
5 likewise in analogy to the abovementioned compounds, introducing the group R'.
The compounds of the general formulae (III), (V), (VI) and (VIII) are known per se or
can be plel)al~d by customary methods.
The compounds of the general formula (IV) are new and can be prepared by,
in known amines of the general formula (IX),
H E
~NH (IX),
L
in which
E and L have the me~ning indicated above,
first protecting the free amino function with ClC02CH2C6Hs in tetrahydrofuran at pH
10 and in a second step carrying out an alkylation (D' ~ H) according to the conditions
15 mentioned above.
The blocking of the free amino function is carried out in a temperature range from
21 94~5
Le A 31 477- Forei~n countries
- 26 -
150C to 200C, preferably at 180C and normal pressure.
The compounds of the general formulae (Ia) - (Ig) are new and can each be prepared
as described above.
The minimum inhibitory concentrations (MIC) were deterrnin.ocl by the serial dilution
- 5 method on Iso-Sensitest agar (Oxoid). For each test substance, a number of agar plates
were prepared which, at twice the dilution in each case, contained falling
concentrations of the active compound. The agar plates were inoculated using a
multipoint inoculator (Denley). For inoculation, overnight cultures of the pathogenic
org~ni~m~ were used which had previously been diluted such that each inoculation10 point contained about 104 colony-forming particles. The inoculated agar plates were
incubated at 37C, and the microbial growth was read off after about 20 hours. The
MIC (llg/ml) indicates the lowest active compound concentration at which it was not
possible to detect growth using the naked eye.
MICs (~g/ml):
Ex. S~ph. S~ph. S~ph S~ph E.coli h~ebs.57 Psdm. Bonn
No. 133 48N 25701 91rV Neumann USA ~~
3 2 2 2 1 >64 ~64 >64
4 4 8 4 2 >64 >64
16 16 16 8 >64 ~64 >64
7 8 8 8 2 >32 >32 >32
12 8 8 8 4 >64 >64 >64
For rapidly growing mycobacteria, the MIC determination was carried out following the
method of broth microdilution described by Swenson [cf. J.M. Swenson, C. Thornberry,
U.A. Silcox, Rapidly growing mycobacteria. Testing of susceptibility to 34
25 antimicrobial agents by broth microdilution. Antimicrobial Agents and Chemotherapy
~_ 21 94945
Le A 31 477- Forei~n countries
- 27 -
Vol. 22, 186-192 (1982)]. A deviation from this was the brain-heart extract medium
treated with 0.1 % by volume of Tween 80.
The mycobacterial strains used were ordered from DSM (German Collection of
Microorg~ni~mc, Brunswick). They were inc~lb~t.od at 37C in a humid chamber.
S The MICs were read off after 2-4 days when the plcl)~dlion-free controls were cloudy
as a result of growth. The MIC is defined as the lowest plepaldlion concentration
which completely inhibits macroscopically visible growth.
MICs: Mycobactenum smegmatis
Stlain: DSM 43061 DSM 43465
Inoculum 2.20U+04 3.10U+04
[/ml]
Ex. No.
3 2 8
4 4 8
6 8 4
Isoniazide 4
Streptomycin 4 4
The compounds of the general formulae (I), (Ia), (Ib), (Ic), (Id), (Ie), (If) and (Ig) have,
combined with low toxicity, a wide antibacterial spectrum, especially against grarn-
20 positive bacteria and mycobacteria, Haemophilus influenzae and anaerobic
nicroorg~ni~m~ for rapidly growing mycobacteria. These properties make possible theiruse as chemotherapeutic active compounds in human and veterinary medicine.
The compounds according to the invention are particularly efficacious against bacteria
21 94945
-
and bacteria-like microorganisms such as mycoplasma. They are
therefore particularly highly suitable for the prophylaxis and
chemotherapy of local and systemic infections in human and
veterinary medicine caused by such pathogenic organisms.
The present invention includes pharmaceutical
preparations which, in addition to non-toxic, inert pharma-
ceutically suitable excipients, contain one or more compounds
according to the invention or which consist of one or more
active compounds according to the invention, and processes for
the production of these preparations. The invention also
extends to commercial packages containing a compound of the
invention, together with instructions for its use combating
pathogenic organisms.
The active compound(s) can optionally also be present
in microencapsulated form in one or more of the excipients
indicated above.
Therapeutically active compounds should be present
in the above-mentioned pharmaceutical preparations in a
concentration of approximately 0.1 to 99.5, preferably of
approximately 0.5 to 95, ~ by weight of the total mixture.
Apart from the compounds according to the invention,
the above-mentioned pharmaceutical preparations can also
contain further pharmaceutical active compounds.
In general, it has proven advantageous both in human
and in veterinary medicine to administer the active compound(s)
according to the invention in total amounts of approximately
0.5 to approximately 500, preferably 5 to 100, mg/kg of body
- 28 -
23189-8043
21 94945
weight every 24 hours, if appropriate in the form of several
individual doses, to achieve the desired results. An
individual dose contains the active compound(s) according to
the invention preferably in amounts from approximately 1 to
approximately 80, in particular 3 to 30, mg/kg of body weight.
For the purpose of widening the spectrum of action
and in order to achieve an increase in action, the compounds
according to the invention can also be combined with other
antibiotics.
- 28a -
23189-8043
21 94945
Le A 31 477- Forei~n countries
- 29 -
Appendix to the experimental section
Abbreviations:
Z Benzyloxycarbonyl
Boc tert-Butoxycarbonyl
DMF Dimethylformamide
Ph Phenyl
Me Methyl
THF Tetrahydrofuran
CDI Carbonyldiimidazole
DCE Dichloroethane
Sta~ Compounds
Example I
6-Benzyloxycarbonylamino-quinoline
~ I o ~3
13.0 ml (76.28 mmol) of benzyl chloroformate are added dropwise in the course of 30
min to a stirred solution of 10.0 g (69.36 mmol) of 6-aminoquinoline in 160 ml of
water and 80 ml of THF which is cooled to 0C, pH = 10 being m~int~ined by
simultaneous addition of a 4 N NaOH solution. The mixture is stirred at 0C for a
further 2 h, the THF is evaporated in vacuo and the residue is extracted 3 times with
20 50 ml of ethyl acetate. The combined orgar., extracts are dried over MgSO4, the
solvent is evaporated in vacuo and the residue is purified by chromatography on 450 g
of silica gel (toluene: ethyl acetate 1:4). 11.60 g (60%) of the title compound are
obtained as crystals.
~ 2 1 94945
Le A 31 477- Forei~n countries
- 30 -
Melting point: 122C
Rf = 0.43 (toluene: ethyl acetate 1 :4)
MS (EI) m/z= 278 (M+)
'H-NMR (300 MHz, D6-DMSO): ~ = 5.22 (s, 2H, CH2O); 7.3 - 7.5 (m, 6H, Ph,
quinoline-H); 7.78 (dd, J = 1.5, 9 Hz, lH, quinoline-H); 7.96 (d, J = 9 Hz, lH,
quinoline-H); 8.17 (d, J = 1.5 Hz, lH, quinoline H-S); 8.25 (d, J = 9 Hz, lH, quinoline-
H); 8.77 (m, lH, quinoline H-2).
Example II
(SR)-3 -(Quinolin-6-yl)-5-hydroxymethyl-oxazolidin-2-one
~N O
-- OH
A stirred solution of 3.28 g (11.78 mmol of 6-benzyloxycarbonylamino-quinoline and
1 mg of 1,10-ph~ oline hydrate in 30 ml of anhydrous THF which is cooled to
-78C is treated slowly with 4.70 ml (11.78 mmol) of a 2.5 M solution of n-
butyllithium in n-hexane until it changes colour. 1.67 ml (11.78 mmol) of (R)-glycidyl
butyrate are then added dropwise and the reaction mixture is allowed to warm to room
temperature in the course of 16 h. 30 ml of saturated aqueous NH4Cl solution are then
added dropwise in the course of 15 min. The water phase is extracted 3 times with
60 ml of ethyl acetate, and the organic phases are combined, washed twice with 50 ml
of NaCl solution and dried over MgS04. After evaporation of the solvent in vacuo,
tritration of the residue with ether and recry~t~lli7~tion from 25 ml of ethanol, 1.30 g
(45%) of the title compound are obtained as colourless crystals.
Melting point: 165C
R~ = 0.08 (toluene: ethyl acetate 1 :4)
MS (DCI, NH3) m/z = 245 (M+H)+
lH-NMR (250 MHz, D6-DMSO): ~ = 3.6 - 3.8 (m, 2H, CH2O); 4.00 (dd, J = 7, 10 Hz,
lH, H-4 trans); 4.25 (dd, J = 10, 10 Hz, lH, H-4 cis); 4.78 (m, lH, H-5); 5.25 (t, J = 6
Hz, lH, OH); 7.52 (dd, J = 4, 9 Hz, lH, quinoline H-3); 7.92 (d, J = 1.5 Hz, lH,
Le A 31 477- Foreign countries 2 1 9 4 9 4 5
- 31 -
quinoline H-S); 8.02 (d, J = 10 Hz, lH, quinoline H-8); 8.3 (m, 2H, quinoline H-4.7);
8.82 (m, lH, quinoline H-2).
Example m
(SR)-3-(5-Quinolin-6-yl)-5 -meth~n~sulphonyloxy-methyl-oxazolidin-2-one
S [~\N ~O
--I OSO2CH3
A stirred solution of 48.19 g (197 mmol) of the compound from Example II and 33 ml
(236 mmol) of triethylamine in 300 ml of anhydrous dichloromethane which is cooled
to 0C is slowly treated with 19.80 ml (256 mmoll of meth~nesulphonyl chloride. The
lllixLule is stirred at 0-5C for 10 min and stirred into 700 ml of ice-water. The organic
phase is separated off, washed with 100 ml of saturated NaHCO3 solution and 100 ml
of ice-water and dried over MgS04. The solvent is evaporated in vacuo and the residue
is stirred with 50 ml of ether, filtered off with suction and dried in a high vacuum. 46.0
g (72%) of the title compound are obtained as colourless crystals.
Melting point: 143C
Rf= 0.14 (toluene: ethyl acetate 1:9)
MS (DCI, NH3) m/z = 323 (M+H)+
~H-NMR (200 MHz, D6-DMSO): 8 = 3.27 (s, 3H, OSO2CH3); 4.00 (dd, J = 7, 10 Hz,
lH, H-4 trans); 4.36 (dd, J = 10, 10 Hz, lH, H-4 cis); 4.57 (m, 2H, CH2O); 5.10 (m,
lH, H-5); 7.53 (dd, J = 4, 9 Hz, lH, quinoline H-3); 7.93 (d, J = 1.5 Hz, lH, quinoline
H-5); 8.06 (d, J = 10 Hz, lH, quinoline H-8); 8.25 (dd, J = 1.5, 10 Hz, lH, quinoline
H-7); 8.36 (d, J = 9 Hz, lH, quinoline H-4); 8.84 (m, lH, quinoline H-2).
Example IV
(5R)-3 -(Quinolin-6-yl)-azidomethyl-oxazolidin-2-one
21 94945
Le A 31 477- Foreign countries
- 32 -
1 3
A stirred solution of 4.71 g (14.60 mmol) of the compound from Example III in 16 ml
of anhydrous DMF is treated with 1.14 g (17.52 mmol) of sodium azide and stirred at
70C for 3 h. The mi~ e is allowed to cool to room telllp~ ldlule and is stirred into 50
S ml of ice-water. The reslllting precipitate is separated off by filtration, washed 3 times
with 20 ml of water and dried in air. 3.50 g (89%) of the title compound are obtained
as pale crystals.
Melting point: 92C
Rf= 0.20 (toluene: ethyl acetate 1:9)
MS (DCI, NH3) m/z = 270 (M+H)+
1H-NMR (250 MHz, D6-DMSO): 8 = 3.71 (m, 2H, CH2N3); 3.95 (dd, J = 6, 8 Hz, lH,
H-4 trans); 4.30 (dd, J = 8, 8 Hz, lH, H-4 cis); 4.98 (m, lH, H-5); 7.52 (dd, J = 9 Hz,
lH, quinoline H-3); 7.94 (d, J = 1.5 Hz, lH, quinoline H-5); 8.06 (d, J = 10 Hz, lH,
quinoline H-8); 8.25 (dd, J = 1.5 Hz, 10 Hz, lH, quinoline H-7); 8.34 (d, J = 9 Hz, lH,
quinoline H-4); 8.84 (m, lH, quinoline H-2).
Example V
(SS)-3-(Quinolin-6-yl)-5-aminomethyl-oxazolidin-2-one dihydrochloride
N O
-- NH2 x2 HCI
A stirred solution of 29.38 g (109 mmol) of the compound from Example IV in 80 ml
of 1,2-dimethoxyethane is warmed to 50C. 25 ml (130 rnmol) of trimethyl phosphite
are slowly added dropwise (evolution of gas)- and the mixture is stirred at 90C for 2
hours after addition is complete. 3.3 ml of 6 N HCI are then added dropwise and the
- ~ 21 94945 Le A 31 477- Forei~n countries
- 33 -
mixture is stirred again at 100C for 6.5 h. It is allowed to cool to room tel,.p~ldl~lre
and the resulting oil is separated off. The oil is dissolved in a little acetonitrile, treated
with 50 ml of toluene, concentrated in vacuo and dried over NaOH in a high vacuum.
30.5 g (99%) of the title compound are obtained. The hard foam is recrystallized from
5 ethanol.
M.p.: 80C (dec.)
Rf = 0.37 (acetonitrile: water 4:1)
MS (FAB) m/z= 244 (M+H)+
lH-NMR (250 MHz, D6-DMSO): ~ = 3.35 (m, 2H, CH2NH2); 4.08 (dd, J = 7, 9 Hz,
lH,H-4trans);4.39(dd,J=9,9Hz, lH,H-4cis);5.10(m, lH,H-5);7.90(dd,J=4,
9 Hz, lH, quinoline H-3); 8.17 (d, J = 1.5 Hz, lH, quinoline H-5); 8.3 - 8.6 (m, 3H,
quinoline H-8, 7.5); 8.90 (d, J = 9 Hz, lH, quinoline H-4); 9.10 (m, lH, quinoline H-
2).
Example VI
(5S)-3-(Quinolin-6-yl)-5-acetylaminomethyl-oxazolidin-2-one
N O
-- NH~CH3
A stirred solution of 30.0 g (10~ mmol) of the compound from Example V in 240 mlof THF is treated with a solution of 10 g of sodium hydroxide in 20 ml of water, a pH
of 7.1 resulting. 11.6 ml (120 mmol) of acetic anhydride in 12 ml of THF are slowly
20 added dropwise at 0-5C to this and pH = 9 is m~int~ined by simultaneous addition of
a 5 N aqueous NaOH solution. The mixture is stirred at 0C for 1 h and the solvent is
evaporated in vacuo. The residue is stirred well twice with 40 ml of water, separated
2 1 ~4945
Le A 31 477- Forei~n countries
- 34 -
off and dried in a high vacuum over Sicapent. 19.16 g (62%) of the title compound are
obtained as colourless crystals.
M.p.: 146C
Rf= 0.33 (dichloromethane: methanol 9:1)
5 MS (FAB) m/z = 286 (M+H)+
IH-NMR (250 MHz, D6-DMSO): ~ = 1.85 (s, 3H, COCH3); 3.50 (t, J = 6.5 Hz, 2H,
CH2N); 3.90 (dd, J = 7, 9 HZ, lH, H-4 trans); 4.28 (dd, J = 9, 10 Hz, lH, H-4 cis);
4.80 (m, lH, H-5); 7.52 (dd, J = 4, 9 Hz, lH, quinoline H-3); 7.88 (d, J = 1.5 Hz, lH,
quinoline H-5); 8.05 (d, J = 10 Hz, lH, quinoline H-8); 8.25 (dd, J = 1.5, 10 Hz,
quinoline H-7); 8.34 (d, J = 9 Hz, lH, quinoline H-4); 8.82 (m, lH, quinoline H-2).
Example VII
(5R)-3-(Quinolin-6-yl)-5-acetylaminomethyl-oxazolidin-2-one N-l-oxide
~ N O
A stirred solution of 500 mg (1.75 mmol) of the compound from Example VI in 5 mlof dichloromethane is treated with 832 mg (3.85 mmol) of 80% strength
m-chloroperbenzoic acid and stirred at room tenlp~ .d~ lre for 16 h. The reaction mixture
is then stirred into 20 ml of saturated aqueous Na2CO3 solution. The aqueous phase is
separated off and evaporated in vacuo. 25 ml of toluene and 1.5 g of silica gel are
20 added and the mixture is evaporated again. The residue is purified by chromatography
on 50 g of silica gel (dichloromethane: methanol 4:1). The product-cont~ininF fractions
are combined and treated with 200 ml of ether. The resulting precipitate is separated
off by filtration and dried in a high vacuum. 453 mg (86%) of the title compound are
obtained as colourless crystals.
Le A 31 477- Forei~n countries 2 ! 9 4 9 4 5
- - 35 -
M.p.: 191C (dec.)
Rf = 0.15 (dichlor )meth~ne: methanol 9:1)
MS (FAB) m/z= 302 (M+H)+
'H-NMR (300 MHz, D6-DMSO): ~ = 1.85 (s, 3H, COCH3); 3.50 (m, 2H, CH~N); 3.91
(dd, J = 7, 10 Hz, lH, H-4 trans); 4.28 (dd, J = 10, 10 Hz, lH, H-4 cis); 4.82 (m, lH,
H-5); 7.3 - 7.5 (m, 2H); 7.9 (m, lH); 8.0 (s, lH, quinoline H-5); 8.3 (m, lH); 8.50 (m,
lH, quinoline H-2).
Prepa-a'don Examples
F,Y~ple 1
(5S)-3-(2-Oxo- 1,2-dihydro-quinolin-6-yl)-5-acetylaminomethyl-oxazolidin-2-one
J~
4' 5' 14 51
NH CH
Method A:
A suspension of 2.73 g (9.10 mmol) of the N-oxide from Example VII and 2.59 g
(13.59 mmol) of p-toluenesulphonyl chloride in 35 ml of chloroform is treated with
27.20 ml (27.20 mmol) of a 10% strength aqueous potassium carbonate solution andthoroughly stirred at room temperature for 4 h. The reaction mixture is then evaporated
to dryness and chromatographed on 100 g of silica gel (acetonitrile: water 95:5). The
- product-cont~ining fractions are collected, the solvent is evaporated in vacuo and the
product obtained is dried in a high vacuum. 2.34 g (86% of theory) of the title
compound are obtained as pale beige crystals.
- -- 21 94q45
Le A 31 477- Foreign countries
- 36 -
M.p.: from 207C (dec.)
E~f= 0.40 (acetonitrile: water 9:1)
MS (DCI, NH3) m/z = 302 (M+H)+, 319 (M+NH4)+
'H-NMR (200 MHz, D6-DMSO): ~ = 1.85 (s, 3H, CH3CO); 3.42 (t, J = 6.5 Hz, 2H,
CH2N); 3.78 (dd, J = 7, 9 Hz, lH, H-4 trans); 4.15 (dd, J = 9, 10 Hz, lH, H-4 cis);
4.75 (m, lH, H-5); 6.52 (d, J= 10 Hz, lH, H-3'); 7.32 (d, J = 10 Hz, lH, H-4'); 7.73
(d,J=2Hz,lH,H-5');7.80(dd,J=2,10Hz,lH,H-7');?.91(d,J=lOHz,lH,H-
8'); 8.27 (m, lH, CONH); 11.73 (bs, lH, NH).
Method B:
A stirred suspension of 652 mg (1.90 mmol) of the compound from Example 2 in
20 ml of anhydrous methanol is treated with 66 mg (0.20 mmol) of caesium carbonate
and stirred at room telllpeldl lre for 1 h. The solvent is evaporated in vacuo and the
residue is stirred with 30 ml of ether. The precipitate is separated off by filtration,
washed with 25 ml of water and 5 ml of ether and dried in a high vacuum. 358 mg
(57%) of the title compound are obtained as pale crystals.
- M.p.: 232-233C
The other physical data are identical with the compound obtained by Method A.
Example 2
(5S)-5-[(Bisacetyl)aminomethyl]-3-(2-oxo- 1,2-dihydro-quinolin-6-yl)-oxazolidin-2-one
~ J~ O~CH,
~ N )1 CH3
- 21 9~945
Le A 31 477- Forei~n countries
- 37 -
A stirred suspension of 5.45 g (10.53 mmol) of the anhydrous N-oxide from Example
VII in 50 ml of acetic anhydride is heated at reflux for 24 h, a clear solution resulting.
The ~ e is allowed to cool and is concentrated to dryness on a rotary evaporator.
The residue is treated with 30 ml of toluene and again concentrated to dryness. This
process is repeated two more times, then the crude product is purified by filtration on
10 g of silica gel (dichloromethane: methanol 95:5) and by chromatography on 100 g
of silica gel (acetonitrile: water 98:2). 1.84 g (58%) of the title compound areobtained.
M.p.: 135- 137C
Rf= 0.33 (dichloromethane: methanol 9:1)/0.48 (acetonitrile: water 95:5)
MS (DCI, NH3) m/z = 344 (M+H)+
'H-NMR (200 MHz, D6-DMSO): ~ = 2.38 (s, 6H, CH3CO); 3.84 (dd, J = 7, 9 Hz, lH-
H-4 trans); 4.10 (m, 2H, CH2N); 4.20 (dd, J = 9, 10 Hz, lH, H-4 cis); 4.82 (m, lH, H-
5); 6.52 (d, J = 10 Hz, lH, H-3'); 7.33 (d, J = 10 Hz, lH, H-4'); 7.78 (m, 2H; H-5', H-
7'); 7.92 (d, J = 10 Hz, lH, H-8'); 11.78 (bs, lH, NH).
IR (KBr): v = 3449, 1735, 1701, 1654, 1560, 1507, 1437 cm~l.
F.Ys~rle 3
(5 S)-3 -(1 -Methyl-2-oxo- 1,2-dihydro-quinolin-6-yl)-5 -acetylaminomethyl-oxazolidin-2-
one
Cl H3
~ ~N O H
~ N ~1 CH3
A suspension of 100 mg (0.33 mmol) of the compound from Example 1 and 1.36 mg
(0.99 mmol) of potassium carbonate in 4 ml of anhydrous DMF is treated with 67 ~11
(1.73 mmol) of iodomethane and stirred at 70C for 1 h. The reaction mixture is then
- 21 94945
Le A 31 477- Forei~n countries
- 38 -
concentrated to dryness, the residue is treated with a mixture of 20 ml of water and 10
ml of dichloromethane, the organic phase is separated off and the aqueous phase is
extracted several times with dichloromethane. The combined extracts are dried over
MgSO4. The solvent is evaporated in vacuo, and the residue is purified by
chromatography on 10 g of silica gel (dichloromethane: methanol 95:5). 60 mg (59%)
of the title compound are obtained as colourless crystals.
M.p.: 252C
Rf= 0.29 (dichloromethane: methanol 9:1)
MS (DCI, NH3) m/z = 316 (M+H)+
'H-NMR (200 MHz, D6-DMSO): 8 = 1.85 (s, 3H, CH3CO); 3.44 (m, 2H CH.N); 3.60
(s, 3H, NCH3); 3.81 (dd, J = 7, 9 Hz, lH, H-4 trans); 4.17 (dd, J = 9, 10 Hz, lH, H-4
cis); 4.78 (m, lH, H-5); 6.65 (d, J = 10 Hz, lH, H-3'); 7.59 (d, J = 10 Hz, lH, H-4');
7.80 (d, J = 1.5 Hz, lH, H-5'); 7.92 (m, 2H, H-7', H-8'); 8.28 (t, J = 6 Hz, lH, CONH).
IR (KBr): v = 3291, 1740, 1664, 1560, 1449, 1231, 1116, 812, 536 cm-l
15 As described for Example 3, the products listed in Table 1 are obtained by alkylation
of the compound from Example 1 with the app,op,;ate alkyl iodides:
21 94~45
Le A 31 477- Foreign countries
- 39 -
Table 1:
~ N O H
Ex. D Yield (/O M.p. R, MS (DC~,
No. of theoly) (C) (CH2CI2:MeOH) NH3), m/z
(la'do) (M+H)+
4 CH2CH3 45 196 0.39, (9:1) 330
CH(CH3)2 21 189 0.25, (95:5) 344
6 CH2CNa) 32 185 0.13, (9:1) 341
7 CH2CH2OH 51 174 0.57, (85:15) 346
8 CH2Ph b) 26 129 0.28, (9:1) 392
a) using CICH2CN b) using BrCH2Ph
21 94945
Le A 31 477- Foreign countries
- 40 -
Example 9
(5S)-3-(1 -[Acetamido-2-yl]-2-oxo- 1,2-dihydro-quinolin-6-yl)-5-acetylaminomethyl-
oxazolidin-2-one
1l
--NH2
~N O H
--~ N CH
~ 3
A solution of 10 mg (0.03 mmol) of the cyano compound from Example 5 in 0.2 ml
of acetone is treated ~,vith 60 ~1 (0.06 mmol) of a lM aqueous potassium c~l,ondle
solution and with 40 1ll (0.18 mmol) of 30% H2O2 and is stirred at room te~c;ldlule
for 2 h. The reaction mixture is then treated with 1 ml of toluene and evaporated to
dryness in vacuo, and the residue is purified by chromatography on 1 g of silica gel
(dichloromethane: methanol 95:5). 7.2 mg (66%) of the title compound are obtained
as colourless crystals.
Rf = 0.11 (dichloromethane: methanol 9: 1)
MS (DCI, NH3) m/z = 359 (M+H)+, 376 (M+NH4)+
'H-NMR (200 MHz, D6-DMSO): 8 = 1.85 (s, 3H, COCH3); 3.45 (m, 2H CH2N); 3.79
(dd, J = 6, 9 Hz, lH, H-4 trans); 4.18 (dd, J = 9, 10 Hz, lH, H-4 cis); 4.77 (m, lH,
H-5); 4.88 (s, 2H, NCH2CON); 6.65 (d, J = 10 Hz, lH, H-3'); 7.27 (bs, lH, CONH2);
7.32 (d, J = 10 Hz, lH, H-4'); 7.70 (bs, lH, CONH2); 7.85 (m, 2H, H-5', H-7'); 7.96 (d,
J = 10 Hz, lH, H-8'); 8.28 (t, J = 6.5 Hz, lH, CONHCH2).
~ 21 9~945
Le A 31 477- Foreign countries
- 41 -
Example 10
(5 S)-3 -(1 -Hydroxymethyl-2-oxo- 1 ,2-dihydro-quinolin-6-yl)-5 -acetaminomethyl-
oxæolidin-2-one
~OH
~3\N O H
~--N~CH3
A stirred suspension of 100 mg (0.33 mmol) of the compound from Example 1 in
3.3 ml (3.3 mmol) of 30% strength aqueous formalin solution is heated to reflux for
2 h. It is then evaporated to dryness in vacuo, and the residue is treated with 10 ml of
toluene and evaporated again. The residual solid is Ifllu-al~d with S ml of ether, filtered
off with suction and dried in a high vacuum. 104 mg (95%) of the title compound are
obtained as a pale powder.
F.Y~n~ple 11
(SS)-3-(1 -N,N-[Dimethylamino-methyl]-2-oxo-1 ,2-dihydro-quinolin-6-yl)-5-
~cet~minl-methyl-oxæolidin-2-one
N(CH3)2
N O H
~-- ~ CH3
.. O
500 mg (0.48 mmol) of the compound from Example 1 are dissolved in 5 ml of hot
ethanol, treated with 0.36 ml of 30% strength aqueous formalin solution and 46 ~Ll
-- 21 94945
Le A 31 477- Forei~n countries
- 42 -
(0.53 mmol) of 51% strength aqueous dimethylamine solution and heated to reflux for
8 h. Working up was carried out as described for Example 9. 139 mg (81%) of the title
compound are obtained as a solid.
Example 12
(5S)-3~ Methanesulphonyl-2-oxo-1,2-dihydro-quinolin-6-yl)-5-acetylaminomethyl-
oxazolidin-2-one
02CH3
~N O H
-- N ~1 CH3
A stirred solution of 100 mg (0.33 mmol) of the compound from Example 1 and 0.56ml (3.96 mmol) of triethylamine in 10 ml of anhydrous dichloromethane which is
cooled to 0C is slowly treated with 0.27 ml (3.44 mmol) of methanesulphonyl
chloride. The mixture is stirred for 4 h at 20C and stirred into 5 ml of ice-water. The
organic phase is separated off, washed with 5 ml of saturated NaHCO3 solution and
dried over MgSO4. The solvent is evaporated in vacuo and the residue is purified by
chromatography on 5 g of silica gel (dichloromethane: methanol 95:5). 224 mg (20%)
of the title compound are obtained as colourless crystals.
M.p.: 171-173C
Rf= 0.72 (acetonitrile: water 95:5)
MS (FAB) m/z = 380 (M+H)+, 402 (M+Na)+
'H-NMR (200 MHz, D6-DMSO): ~ = 1.84 (s, 3H, COCH3); 3.48 (t, J = 6 Hz, 2H
CH2N); 3.79 (s, 3H, CH3SO2); 3.90 (dd, J = 7, 9 Hz, lH, H4 trans); 4.27 (dd, J = 9,
9 Hz, lH, H-4 cis); 4.80 (m, lH, H-5); 7.42 (d, J = 10 Hz, lH, H-3'); 8.03 (m, 2H, H-
4', H-5'); 8.30 (m, 7H, H-7', CONH); 8.59 (d, J= 10 Hz, lH, H-8').
-- 2 1 94 945
Le A 31 477- Forei~n countries
- 43 -
IR (KBr): v = 3338, 1734, 1654, 1600, 1549, 1517, 1364, 1170, 1140, 986, 813, 528
cm-l
Example 13
(5 S)-3 -(1 -[3 -Chlorobenzoyl] -2-oxo- 1,2-dihydro-quinolin-6-yl)-acetaminomethyl-
5 oxazolidin-2-one
\~\CI
~N O H
175 mg (1.00 mmol) of 3-chlorobenzoyl chloride are added slowly to a stirred solution
of 150 mg (0.50 mmol) ofthe compound from Example 1 and 0.21 ml (1.50 mmol) of
triethylamine in 5 ml of anhydrous DMF which is cooled to 0C. The mixture is stirred
for 2 h at 0C and diluted with 20 ml of water and 50 ml of dichloromethane, theorganic phase is separated off, the aqueous phase is extracted several times with 5 ml
of dichloromethane and the combined organic extracts are dried over MgS04. Afterevaporating the solvent in vacuo, purifying the crude product by chromatography on 15
g of silica gel (dichloromethane: methanol 95:5) and tritrating the residue with ether,
15 95 mg (43%) of the title compound are obtained as crystals.
M.p.: 172-174C
R~= 0.47 (dichlor~ nethane: methanol 9:1)
MS (DCI, NH3): m/z = 440 (M+H)+
IH-NMR (300 MHz, D6-DMSO): 8 = 1.86 (s, 3H, COCH3); 3.50 (t, J = 6 Hz, 2H
CH2N); 3.92 (dd, J = 7, 9 Hz, lH, H-4 trans); 4.30 (dd, J = 9, 10 Hz, lH, H-4 cis);
21 94945
Le A 31 477- Forei~n countries
- 44 -
4.82 (m, lH, H-5); 7.56 (d, J = 10 Hz, lH, H-3'); 7.65 - 8.35 (m, 8H, H-arom.,
CONH); 8.58 (d, J = 9 Hz, lH, H-8');
IR (KBr): v = 3284, 1740, 1654, 1560, 1517, 1424, 1258, 1216, 888, 740 cm-
Example 14
- 5 (5S)-5-(N-Acetyl,N-(2-cyanoethyl)aminomethyl-3-(2-oxo-1,2-dihydro-quinolin-6-yl)-
oxazolidin-2-one
~NJ~O
--~ N ~1 CH3
100 mg (0.33 mmol) of the compound from Example 1 are added in portions to a
stirred suspension of 16 mg (0.40 mmol) of sodium hydride (60% in oil) in 2 ml of
anhydrous DMF which is cooled to 0C and the mixture is stirred until evolution of
hydrogen has ended. 65 ~l (0.99 mmol) of acrylonitrile are added dropwise to theresulting clear solution in the course of 5 min. The cooling bath is removed, and after
15 min the reaction is terrnin~ted by addition of 1 ml of 1 N citric acid. The reaction
mixture is poured into a ~ e of 10 ml of dichloromethane and 5 ml of water and
thoroughly stirred. The organic phase is separated off, the water phase is extracted
several times with 5 ml of dichloromethane and the combined extracts are dried over
MgSO4. The solvent is evaporated in vacuo and the residue is purified by
chromatography on 5 g of silica gel (dichloromethane: methanol 95:5). 30 mg (26%)
of the title compound are obtained as col~urless crystals.
M.p.: 124-125C
Rf = 0.17 (dichloromethane: methanol 9: 1)
MS (FAB) m/z = 355 (M+H)+
Le A 31 477- Forei~n countries 2 1 9 4 9 4 5
- 45 -
'H-NMR (250 MHz, D6-DMSO): ~ = 2.08, 2.12 (s, 3H, COCH3); 2.70 - 2.90 (m, 2H,
CH2CN); 3.5 - 3.9 (m, SH, CH2N, H-4 trans); 4.15 (dd, J = 9, 10 Hz, lH, H-4 cis);
4.90 (m, lH, H-S); 6.52 (d, J = 10 Hz, lH, H-3'); 7.31 (d, J = 10 Hz, lH, H-4'); 7.80
(m, 2H, H-5', H-7'); 7.91 (dd, J = 2, 10 Hz, lH, H-8'); 11.90 (bs, lH, NH).
5 The Michael adduct described in Table 2 is obtained in analogy to Example 14:
Table 2:
O N ~ R33
~N O
CH3
O
Ex. R33 Yield Rr/ Eluent MS (FAB),
No. (%of (ratio) m/z (M+H)+
theoly)
COOCH3 18 0.14, I (9:1) 388
Le A 31 477- Forei~n countries 2 1 9 4 9 4 5
- 46 -
FY~n~rle 16
(SS)-3-(1-[N,N'-Dimethyl-ureido-carbonyl]-2-oxo-1 ,2-dihydro-quinolin-6-yl)-5-
acetylaminomethyl-oxazolidin-2-one
O~,N~CH
Oq~N~cH
N O H
~ CH3
A suspension of 100 mg (0.33 mmol) of the compound from Example 1 in 1.8 ml of
DMF is treated with 0.58 ml (10.0 mmol) of methyl isocyanate and 0.69 ml (5.0 mmol)
of triethylamine and stirred at 50C for 100 h. The reaction mixture is then allowed to
cool and the volatile constituents are removed in vacuo. The residue is purified by
chromatography on 25 g of silica gel (dichloromt;~hane: methanol 95:5). The product-
0 cont~ining fractions are collected and the solvent is evaporated in vacuo. The residue
is dissolved in 0.2 ml of dichloromethane: methanol 95:5 and pleci~ilaled by slow
addition of 2 ml of ether and 2 ml of pentane. 22 mg (19%) of the title compound are
obtained as pale crystals.
M.p.: from 1 12C (dec.)
Rf= 0.14 (dichloromethane: methanol 9:1)
MS (FAB) m/z = 416 (M+H)+, 438 (M+Na)+
~H-NMR (200 MHz, D6-DMSO): ~ = 1.85 (S7 3H, COCH3); 2.85 (m, 3H, CH3N); 2.96
(s, 3H, CH3N); 3.44 (t, J = 5 Hz, 2H, CH2N); 3.81 (dd, J = 6, 9 Hz, lH, H-4 trans);
4.19 (dd, J = 9, 10 Hz, lH, H-4 cis); 4.78 (m, lH, H-5); 5.73 (bs, lH, CONHCH3);6.72 (d, J= 10 Hz, lH, H-3'); 7.30 (d, J= 10 Hz, H-4'); 7.90 (m, 2H, H-5', H-7'); 8.12
- ~ 21 94945
Le A 31 477- Forei~n countries
- 47 -
(d, J = 10 Hz, IH, H-8'); 8.28 (t, J = 6 Hz, IH, CONHCH~).
Example 17
(SS)-3-(1-Methyl-2-oxo-1,2-dihydro-quinolin-6-yl)-5-thioacetylaminomethyl-oxazolidin-
2-one
ICH3
S ~N O H
A stirred solution of 125 mg (0.40 mmol) of the compound from Example 3 and 162
mg (0.40 mmol) of Lawesson's reagent in 5 ml of anhydrous 1,2-dimethoxyethane was
heated at 100C for 2 h. The reaction mixture was then allowed to cool, 20 g of silica
gel were added and the solvent was evaporated in vacuo. The residue was added to a
column and purified by chromatography on 200 g of silica gel (ethyl acetate). 22 mg
(17%) of the title compound were obtained as pale crystals.
M.p.: 158- 160C
Rf= 0.46 (dichloromethane: methanol 9:1)
MS (DCI, NH3) m/z= 332 (M+H)+
IH-NMR (200 MHz, D6-DMSO): ô = 2.45 (s, 3H, CH3CS); 3.61 (s, 3H, NCH3); 3.8 -
4.0 (m, 3H, CH2N, H-4 trans); 4.22 (dd, J = 9, 10 Hz, lH, H-4 cis); 5.00 (m, lH, H-5);
6.65 (d, J = 10 Hz, lH, H-3); 7.58 (d, J = 10 Hz, lH, H-4'); 7.82 (d, J = 1.5 Hz, lH,
H-5'); 7.9 (m, 2H, H-7', H-8'); 10.41 (bt, lH, CONH).
